Sugi Predict

Sugi Predict / Compounds / SCHEMBL187003

SCHEMBL187003

SCHEMBL187003

Clc1ccc(C2CCNCC2)cc1

nearest known ligand 0.77

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HTR3A P46098 1/20 0.77
▸ SLC18A3 Q16572 1/20 0.61
▸ SIGMAR1 Q99720 1/20 0.61
▸ HTR2C P28335 3/20 0.57
▸ QDPR P09417 1/20 0.52
▸ SLC6A2 P23975 1/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ DRD2 P14416 1/20 0.47
▸ MAPKAPK2 P49137 1/20 0.47
▸ GABRA1 P14867 1/20 0.45
▸ GABRG2 P18507 1/20 0.45
▸ GABRB3 P28472 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL557429 0.98 HTR3A (0.74) HTR3ASLC18A3SIGMAR1HTR2CQDPR
Hydrochloric Acid SCHEMBL23411632 0.96 HTR3A (0.71) HTR3ASLC18A3SIGMAR1HTR2CQDPR
SCHEMBL29892091 0.92 HTR3A (0.72) HTR3ASLC18A3SIGMAR1HTR2CQDPR
SCHEMBL23411573 0.92 HTR3A (0.72) HTR3ASLC18A3SIGMAR1HTR2CQDPR
SCHEMBL12536782 0.87 HTR3A (0.66) HTR3ASLC18A3SIGMAR1SLC6A2SLC6A3
SCHEMBL6902944 0.87 HTR3A (1.00) HTR3ASLC6A2SLC6A3
SCHEMBL447190 0.87 HTR3A (1.00) HTR3ASLC6A2SLC6A3
SCHEMBL26690667 0.87 HTR3A (1.00) HTR3ASLC6A2SLC6A3
Hydrochloric Acid SCHEMBL4573036 0.85 HTR3A (0.96) HTR3ASLC6A2SLC6A3
Hydrochloric Acid SCHEMBL29908691 0.85 HTR3A (0.96) HTR3ASLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 550 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116768826-B Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof 中国科学院新疆理化技术研究所 2025-05-27 — — CN claimed
CN-116768826-A Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof 中国科学院新疆理化技术研究所 2023-09-19 — — CN claimed
US-20130245064-A1 NOVEL NEUROTRYPSIN INHIBITORS NEUROTUNE AG (CH) 2013-09-19 — — US claimed
EP-2635554-A2 NOVEL NEUROTRYPSIN INHIBITORS Neurotune AG (CH) 2013-09-11 — — EP claimed
WO-2012059443-A2 NOVEL NEUROTRYPSIN INHIBITORS NEUROTUNE AG (CH) 2012-05-10 — — WO claimed
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 — — EP claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 — — US claimed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 — — EP claimed
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
EP-4731223-A1 MORPHOLINE AND 1,4-OXAZEPANE COMPOUNDS AND ITS USE IN THERAPY Universitat De Barcelona (ES) 2026-04-29 — — EP disclosed
US-20260070884-A1 Inhibitors of Dihydroceramide Desaturase for Treating Disease CENTAURUS THERAPEUTICS (US) 2026-03-12 — — US disclosed
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) 2025-11-25 — — US disclosed
US-12479816-B2 20-HETE formation inhibitors University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-11-25 — — US disclosed
US-20250263426-A1 PDE4B INHIBITOR AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 — — US disclosed
US-4177290-A CNS ACTIVITY LABORATOIRE L. LAFON (FR) 1979-12-04 — — US disclosed
US-4077958-A ANTIDEPRESSANTS E. R. SQUIBB & SONS, INC. (US) 1978-03-07 — — US disclosed
US-4053477-A 5-(1,1-DIPHENYL-3-(4-PHENYLPIPERIDINO)PROPYL)-2-METHYL-1,3,4-OXADIAZOLE AND RELATED COMPOUNDS G. D. SEARLE & CO. (US) 1977-10-11 — — US disclosed
US-4007191-A ANTIDEPRESSANT E. R. SQUIBB & SONS, INC. (US) 1977-02-08 — — US disclosed
US-3936464-A HYPOTENSIVE AMERICAN CYANAMID COMPANY (US) 1976-02-03 — — US disclosed
US-3935227-A ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS E. R. SQUIBB & SONS, INC. (US) 1976-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R HTR3A 741/4885SLC18A3 3852/4885SIGMAR1 480/4885
US-20260070884-A1 Inhibitors of Dihydroceramide Desaturase for Treating Disease CERS2, DEGS1, CERT1 HTR3A 3484/4885SLC18A3 2364/4885SIGMAR1 800/4885
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 HTR3A 1734/4885SLC18A3 4755/4885SIGMAR1 47/4885
US-12478621-B2 Substituted aminoquinolones as dgkalpha inhibitors for immune activation DGKK, DGKG, DGKA HTR3A 4516/4885SLC18A3 4364/4885SIGMAR1 4076/4885
US-20250263426-A1 PDE4B INHIBITOR AND USE THEREOF PDE4B, PDE4A, PDE3B HTR3A 3096/4885SLC18A3 4102/4885SIGMAR1 4440/4885
US-12479816-B2 20-HETE formation inhibitors CYP4A22, ALOX5, ALOX15 HTR3A 315/4885SLC18A3 919/4885SIGMAR1 2679/4885
US-20130245064-A1 NOVEL NEUROTRYPSIN INHIBITORS PRSS12, NLN, MTPN HTR3A 1508/4885SLC18A3 78/4885SIGMAR1 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.